Vor Biopharma director granted 53,283 stock options

Vor Biopharma director Daniella Beckman received a grant of 53,283 stock options to buy Vor Biopharma common stock at an exercise price of $14.09 per share.

Rhea-AI Filing Summary

Vor Biopharma director Daniella Beckman received a grant of 53,283 stock options to buy Vor Biopharma common stock at an exercise price of $14.09 per share. These options were awarded as compensation and are held directly.

According to the vesting schedule, one thirty-sixth of the options will vest and become exercisable on July 11, 2026, with additional installments vesting monthly thereafter, as long as she continues to serve the company. After this grant, she holds stock options covering 53,283 underlying shares, which will expire on June 10, 2036 if not exercised.

Insider Trade Summary

Grant/Award: 53,283 shares

Grant/Award 1 txn

Insider Beckman Daniella

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	53,283	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 53,283 contracts (Direct)

Footnotes (1)

1. F1. One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

Stock options granted: 53,283 options Exercise price: $14.09 per share Underlying shares: 53,283 shares +3 more

6 metrics

Stock options granted 53,283 options Grant to director on June 11, 2026

Exercise price $14.09 per share Strike price for the 53,283 options

Underlying shares 53,283 shares Common stock underlying the option grant

Post-transaction option holdings 53,283 options Total derivative holdings following grant

Vesting start date July 11, 2026 First vesting date for one thirty-sixth of options

Expiration date June 10, 2036 Option expiration if not exercised

Key Terms

Stock option (right to buy), exercise price, vesting, expiration date

4 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 14.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option shall vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vor Biopharma (VOR) report for Daniella Beckman?

Vor Biopharma reported that director Daniella Beckman received a grant of 53,283 stock options. These options give her the right to buy common shares at an exercise price of $14.09 per share, subject to a multi-year vesting schedule tied to continued service.

What is the size and exercise price of Daniella Beckman’s Vor Biopharma (VOR) stock option grant?

The grant covers 53,283 stock options with an exercise price of $14.09 per share. This means she can buy up to 53,283 Vor Biopharma common shares at that fixed price once the options vest and become exercisable over time.

How do Daniella Beckman’s Vor Biopharma (VOR) options vest over time?

One thirty-sixth of the 53,283 options will vest on July 11, 2026, with additional installments vesting each month afterward. Vesting continues only if she remains in service, creating a long-term alignment between her compensation and ongoing involvement with Vor Biopharma.

When do Daniella Beckman’s Vor Biopharma (VOR) stock options expire?

The stock options are scheduled to expire on June 10, 2036. If they are not exercised by that date, they will lapse. This expiration date sets a long-term window during which vested options can potentially be used to purchase Vor Biopharma common shares.

How many Vor Biopharma (VOR) options does Daniella Beckman hold after this transaction?

Following this grant, Daniella Beckman holds stock options covering 53,283 underlying shares of Vor Biopharma common stock. The Form 4 indicates these options are held directly and that this award represents her reported derivative position in the company after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 08:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beckman Daniella

(Last) (First) (Middle)

500 BOYLSTON STREET, SUITE 1350

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$14.09	06/11/2026		A		53,283		(1)	06/10/2036	Common stock	53,283	$0	53,283	D

Explanation of Responses:

1. One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Adi Osovsky, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)